Correlation study between 68Ga-DOTATOC PET/CT metrics and 177Lu-DOTATATE dosimetry for non-pancreatic neuroendocrine tumors

#3467

Introduction: 177Lu-DOTATATE therapy is validated for the management of well-differentiated metastatic, somatostatin receptor expressing non-pancreatic neuroendocrine tumors (npNETs). The evaluation of the tissue absorbed dose (D) could allow to assess the risk-benefit ratio of PRRT. Unfortunately, due its complexity, dosimetry study is hardly performed in routine.

Aim(s): Our retrospective single-centre study aims to investigate a correlation between tumor D after the first cycle of PRRT and parameters of pretherapeutic 68Ga-DOTATOC PET/CT in patients with metastatic npNETs.

Materials and methods: The parameters studied in PET/CT were the SUVmax, SUVmean, SUVpeak of each lesion and the ratio with liver and spleen SUVmean. Dosimetry was done on Planet®Dose (DOSIsoft) from 4 SPECT/CT performed 4, 24, 72 and 144h after the injection of 7.4GBq of 177Lu-DOTATATE. The correlation study was achieved with the Pearson method (α: 5%).

Conference:

Presenting Author:

Authors: Texier J, Jocmek M, Dierickx L, Vallot D, Brillouet S,

Keywords: 68Ga-DOTATOC PET/CT, non-pancreatic neuroendocrine tumor, 177Lu-DOTATATE, dosimetry,